Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.

Jeong YH, Tantry US, Gurbel PA.

Expert Opin Pharmacother. 2012 Aug;13(12):1771-96. doi: 10.1517/14656566.2012.704909. Review.

PMID:
22783896
2.

Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.

Martin MT, Spinler SA, Nutescu EA.

Clin Ther. 2011 Apr;33(4):425-42. doi: 10.1016/j.clinthera.2011.04.007. Review.

PMID:
21635989
3.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303.

4.

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee..

Am Heart J. 2010 Jul;160(1):16-22.e1. doi: 10.1016/j.ahj.2010.04.022.

PMID:
20598967
5.

Prasugrel hydrochloride for the treatment of acute coronary syndromes.

Lhermusier T, Waksman R.

Expert Opin Pharmacother. 2015 Mar;16(4):585-96. doi: 10.1517/14656566.2015.1005602. Review.

PMID:
25633751
6.

Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction.

Coons JC, Schwier N, Harris J, Seybert AL.

Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):609-20. doi: 10.1517/17425255.2014.890589. Review.

PMID:
24555443
8.

Critical review of prasugrel for formulary decision makers.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2009 May;15(4):335-43. Review.

10.
11.

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators..

Am Heart J. 2006 Oct;152(4):627-35.

PMID:
16996826
12.
13.

Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.

Lyseng-Williamson KA.

Am J Cardiovasc Drugs. 2012 Jun 1;12(3):207-16. doi: 10.2165/11209640-000000000-00000.

PMID:
22583148
14.

Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.

Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, Braunwald E.

Am J Cardiol. 2011 Oct 1;108(7):905-11. doi: 10.1016/j.amjcard.2011.05.020.

PMID:
21816379
15.

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.

Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, Zhou C, Jakubowski JA, White HD, Fox KA, Prabhakaran D, Armstrong PW, Tantry US, Roe MT; TRILOGY ACS Platelet Function Substudy Investigators..

JAMA. 2012 Nov 7;308(17):1785-94. doi: 10.1001/jama.2012.17312.

PMID:
23117779
16.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

17.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323.

18.

The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

Toth PP.

Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955. Review.

PMID:
19179814
19.

[Myocardial infarction: Role of new antiplatelet agents].

Silvain J, Bellemain A, Ecollan P, Montalescot G, Collet JP.

Presse Med. 2011 Jun;40(6):615-24. doi: 10.1016/j.lpm.2011.03.002. Review. French.

PMID:
21511430
20.

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators..

N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512.

Supplemental Content

Support Center